Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SenzaGen ABOSTO:SENZA -0.75%72 Forward Dividend Yield % is 0.00% as of Jul. 25, 2026. GuruFocus rates OSTO:SENZA with a GF Score™ of 72/100 and a GF Value™ of kr6.41 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 61 Medical Diagnostics & Research companies, SenzaGen AB ranks worse than 1639342.62% on this metric.
As of today (2026-07-25), the Forward Annual Dividend Yield of SenzaGen AB is 0.00%.
As of today (2026-07-25), the Trailing Annual Dividend Yield of SenzaGen AB is 0.00%.
OSTO:SENZA's Forward Dividend Yield % is not ranked *
in the Medical Diagnostics & Research industry.
Industry Median: 2.21 * Ranked among companies with meaningful Forward Dividend Yield % only.
The growth rate is calculated with least square regression.
For more information regarding to dividend, please check our Dividend Page.
SenzaGen AB (OSTO:SENZA) Forward Dividend Yield % Explanation
Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.
Dividends may also qualify a lower tax rate for investors.
In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
SenzaGen AB Forward Dividend Yield % Related Terms
OSTO:SENZA vs TMO, DHR, IDXX: Forward Dividend Yield % Comparison
For the Diagnostics & Research subindustry, SenzaGen AB's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
SenzaGen AB Forward Dividend Yield % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, SenzaGen AB's Forward Dividend Yield % distribution charts can be found below:
* The bar in red indicates where SenzaGen AB's Forward Dividend Yield % falls into.
What does a Forward Dividend Yield % of 0.00% mean?
SenzaGen AB (OSTO:SENZA) has a Forward Dividend Yield % of 0.00% as of Jul. 25, 2026. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on SenzaGen AB and its competitors. According to the industry distribution chart, SenzaGen AB ranks #999999 out of 61 companies in the Medical Diagnostics & Research industry.
Is SenzaGen AB's Forward Dividend Yield % too high?
SenzaGen AB's current Forward Dividend Yield % is 0.00%. Based on the distribution chart, SenzaGen AB ranks #999999 out of 61 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, SenzaGen AB has a GF Score™ of 72/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does SenzaGen AB's Forward Dividend Yield % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, SenzaGen AB ranks #999999 out of 61 companies for Forward Dividend Yield %. This places SenzaGen AB in the lower half of its industry. The industry median Forward Dividend Yield % is 2.21. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward Dividend Yield % for a Medical Diagnostics & Research company?
The median Forward Dividend Yield % among Medical Diagnostics & Research companies is 2.21, based on 61 companies in the industry. Companies in the top quartile (top 25%) have a Forward Dividend Yield % significantly above this median, while those in the bottom quartile fall well below. However, Forward Dividend Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward Dividend Yield % mean?
A high Forward Dividend Yield % can signal that a stock is expensive relative to its fundamentals. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on SenzaGen AB and its competitors. For the Medical Diagnostics & Research industry, the median Forward Dividend Yield % is 2.21 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. SenzaGen AB's current Forward Dividend Yield % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SenzaGen AB stock overvalued right now?
Based on GuruFocus' analysis, SenzaGen AB (OSTO:SENZA) is currently considered Modestly Undervalued. The stock's GF Value™ is kr6.41, compared to a current price of kr5.30 — trading 17.3% below its estimated fair value. The current Forward Dividend Yield % is 0.00%. SenzaGen AB's overall GF Score™ is 72/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward Dividend Yield % calculated?
Forward Dividend Yield % is calculated from a company's financial statements. For SenzaGen AB (OSTO:SENZA), the current Forward Dividend Yield % is 0.00% as of Jul. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is SenzaGen AB (OSTO:SENZA) Overvalued in 2026?
Based on GuruFocus' analysis, SenzaGen AB stock appears to be undervalued.
The current stock price of kr5.30 is trading 17.3% below its estimated GF Value™ of kr6.41.
GuruFocus considers SenzaGen AB to be Modestly Undervalued.
Key valuation signals for OSTO:SENZA:
Forward Dividend Yield %: 0.00%
GF Value™: kr6.41 vs. price of kr5.30 (17.3% below fair value)
No single metric tells the full story. See the OSTO:SENZA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
SenzaGen AB markets, sells, and performs in vitro testing using its Genomic Allergen Rapid Detection (GARD) platform through its laboratory and a network of contract research organizations. The company provides animal-free testing solutions for chemical compounds used in industries such as cosmetics, chemicals, pharmaceuticals, medical devices, and food and nutrition. Geographically, it operates in the Americas, EMEA, and APAC, with the majority of revenue from EMEA.
72GF Score
Get the complete analysis for OSTO:SENZA
Forward Dividend Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:SENZA has been successfully added to your 
